Agomab Therapeutics NV (Nasdaq: AGMB) ('Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an ...
NEW YORK, NY / ACCESS Newswire / February 2, 2026 / Iron Dome Acquisition I Corp. ("IDAC"), a blank check company ...
Eikon Therapeutics, Inc. ('Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, ...
Learn how to evaluate new IPOs, understand valuation methods, and decide if you should invest. Key questions can help you assess potential stocks.
On Jan. 30, 2026, K2 Capital Acquisition Corporation (NASDAQ:KTWOU) (the "Company") announced the closing of its upsized ...
Veradermics Inc., a late clinical-stage biopharmaceutical company focused on hair restoration, raised $256.3 million in an ...
NEW YORK, NY / ACCESS Newswire / January 29, 2026 / On January 28, 2026, GigCapital9 Corp. closed its Initial Public ...
Helix Acquisition Corp. III (Nasdaq: HLXC) (the “Company”) announced today that on January 26, 2026, it closed the initial public offering of 17,250,000 Class A ordinary shares, which includes ...
SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced the pricing of its initial public ...
Irish Examiner on MSN
Elon Musk combines firms SpaceX and xAI ahead of expected public offering later this year
The world’s richest man Elon Musk is combining his companies SpaceX and xAI in a deal that values the enlarged entity at ...
Learn how SEC Form 424B4 plays a crucial role in initial public offerings by detailing important information from previous SEC filings, ensuring transparency and investor confidence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results